Literature DB >> 17290028

Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke.

Raquel Delgado-Mederos1, Alex Rovira, José Alvarez-Sabín, Marc Ribó, Josep Munuera, Marta Rubiera, Esteban Santamarina, Olga Maisterra, Pilar Delgado, Joan Montaner, Carlos A Molina.   

Abstract

BACKGROUND AND
PURPOSE: We sought to evaluate the impact of the speed of recanalization on the evolution of diffusion- weighted imaging (DWI) lesions and outcome in stroke patients treated with tissue-type plasminogen activator (tPA).
METHODS: We evaluated 113 consecutive stroke patients with a middle cerebral artery occlusion who were treated with intravenous tPA. All patients underwent multiparametric magnetic resonance imaging studies, including DWI and perfusion-weighted imaging before and 36 to 48 hours after administration of a tPA bolus. Patients were continuously monitored with transcranial Doppler during the first 2 hours after tPA administration. The pattern of recanalization on transcranial Doppler was defined as sudden (<1 minute), stepwise (1 to 29 minutes), or slow (>30 minutes).
RESULTS: During transcranial Doppler monitoring, 13 (12.3%) patients recanalized suddenly, 32 (30.2%) recanalized in a stepwise manner, and 18 (17%) recanalized slowly. Baseline clinical and imaging parameters were similar among recanalization subgroups. At 36 to 48 hours, DWI lesion growth was significantly (P=0.001) smaller after sudden (3.23+/-10.5 cm(3)) compared with stepwise (24.9+/-37 cm(3)), slow (46.3+/-38 cm(3)), and no (51.7+/-34 cm(3)) recanalization. The slow pattern was associated with greater DWI growth (P=0.003), lesser degree of clinical improvement (P=0.021), worse 3-month outcome (P=0.032), and higher mortality (P=0.003).
CONCLUSIONS: The speed of tPA-induced clot lysis predicts DWI lesion evolution and clinical outcome. Unlike sudden and stepwise patterns, slow recanalization is associated with greater DWI lesion growth and poorer short- and long-term outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290028     DOI: 10.1161/01.STR.0000257977.32525.6e

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

1.  Simultaneous combined intravenous recombinant tissue plasminogen activator and endovascular therapy for hyperacute middle cerebral artery m1 occlusion.

Authors:  S Toyota; S Sugiura; K Iwaisako
Journal:  Interv Neuroradiol       Date:  2011-04-29       Impact factor: 1.610

2.  The hemodynamic status within 24 h after intravenous thrombolysis predicts infarct growth in acute ischemic stroke.

Authors:  José Fidel Baizabal-Carvallo; Charlotte Rosso; Marlene Alonso-Juarez; Christine Pires; Yves Samson
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

3.  Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?

Authors:  Benoît Haelewyn; Jean-Jacques Risso; Jacques H Abraini
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-10       Impact factor: 6.200

4.  Transcranial diffuse optical assessment of the microvascular reperfusion after thrombolysis for acute ischemic stroke.

Authors:  Raquel Delgado-Mederos; Clara Gregori-Pla; Peyman Zirak; Igor Blanco; Lavinia Dinia; Rebeca Marín; Turgut Durduran; Joan Martí-Fàbregas
Journal:  Biomed Opt Express       Date:  2018-02-21       Impact factor: 3.732

Review 5.  Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.

Authors:  Denis Vivien; Maxime Gauberti; Axel Montagne; Gilles Defer; Emmanuel Touzé
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

6.  Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.

Authors:  Hélène N David; Benoît Haelewyn; Jean-Jacques Risso; Nathalie Colloc'h; Jacques H Abraini
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

7.  Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation.

Authors:  Qiuyun Zhao; Xiaobo Li; Wanli Dong; Min Ye; Yongjun Cao; Meijuan Zhang; Qiantao Cheng; Junshan Zhou; Guofang Chen; Ming Yu; Shanshan Hong; Xiue Wei; Bei Wang; Guiyun Cui; Peng Zhang; Hong Ding; Rongzhen Xu; Yan Chen; Yun Xu
Journal:  Neurosci Bull       Date:  2016-03-07       Impact factor: 5.203

8.  MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization.

Authors:  Albert J Yoo; Luis A Verduzco; Pamela W Schaefer; Joshua A Hirsch; James D Rabinov; R Gilberto González
Journal:  Stroke       Date:  2009-04-09       Impact factor: 7.914

9.  Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant.

Authors:  Martin R Gaudinski; Erica C Henning; Aaron Miracle; Marie Luby; Steven Warach; Lawrence L Latour
Journal:  Stroke       Date:  2008-07-17       Impact factor: 7.914

10.  Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban.

Authors:  Rüdiger J Seitz; Judith Sukiennik; Mario Siebler
Journal:  Neurol Int       Date:  2012-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.